Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pernix Theraptcs (PTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pernix Theraptcs 10 NORTH PARK PLACE SUITE 201 MORRISTOWN NJ 07960 USA

www.pernixtx.com P: 800-793-2145 F: 862-260-8752

Description:

Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company's product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.

Key Statistics

Overview:

Market Capitalization, $K 28,285
Shares Outstanding, K 11,640
Annual Sales, $ 140,860 K
Annual Net Income, $ -169,590 K
Last Quarter Sales, $ 40,470 K
Last Quarter Net Income, $ 6,360 K
36-Month Beta 1.68
% of Insider Shareholders 1.36%
% of Institutional Shareholders 17.26%

Growth:

1-Year Total Return -12.59%
3-Year Total Return -97.48%
5-Year Total Return -97.21%
5-Year Revenue Growth 132.40%
5-Year Earnings Growth -488.42%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/07/17
Earnings Per Share ttm -9.53
EPS Growth vs. Prev Qtr 73.61%
EPS Growth vs. Prev Year 79.12%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Most Recent Dividend 0.25 on 08/21/01
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 10/14/16

PTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 0.00
Price/Earnings to Growth N/A
Return on Equity % 0.00
Return on Assets % -37.13
Net Margin % 15.07
Debt/Equity -1.71
Price/Sales 0.21
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -12.42
Interest Coverage 1.68
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.